Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00724711 · ClinicalTrials.gov registry record · Phase 4

Safety and Efficacy Study of Switching From Epzicom to Truvada

A Phase 4 study of HIV Infection, sponsored by Gilead Sciences.

Completed
Registry status
Phase 4
Development phase
312
Enrollment target
20
Study locations

NCT00724711 is a Phase 4 study of HIV Infection that has completed, run by Gilead Sciences. The registered enrollment target is 312 participants, above the 239-participant average among 73 other HIV Infection trials with a reported enrollment target (31% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00724711, a Phase 4 study of HIV Infection, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 4
Development phase
312 participants
Enrollment target
20
Study locations

Study Summary

This protocol describes a prospective, randomized, open-label, multicenter study to evaluate the safety and efficacy of switching from fixed dose abacavir (ABC)/lamivudine (3TC) to fixed dose emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in virologically suppressed, human immunodeficiency virus type 1 (HIV-1) infected subjects maintained on a ritonavir-boosted protease inhibitor (PI/r)-containing antiretroviral (ARV) regimen. Duration of treatment is 48 weeks.

Conditions Studied

HIV Infection

Interventions

  • DRUG emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
  • DRUG abacavir (ABC)/lamivudine (3TC)

Study Locations (20)

California

  • Vista Medical Partners - Beverly Hills
  • AHF - Beverly Hills
  • Pacific Oaks Medical Group - Beverly Hills
  • Center for Special Immunology - Fountain Valley
  • Living Hope Clinical Foundation - Long Beach
  • Jeffrey Goodman Special Care Clinic - Los Angeles
  • Peter J. Ruane, MD, Inc. - Los Angeles
  • Anthony M Mills, MD - Los Angeles
  • Orange Coast Medical Group - Newport Beach
  • Tarzana Treatment Center - Northridge
  • Alameda County Medical Center - Oakland
  • Health Management Institute, Inc. - San Francisco
  • Metropolis Medical - San Francisco

Florida

  • Biogenomx Research Institute, LLC - Fort Lauderdale
  • Life Way Inc. - Fort Lauderdale
  • Therafirst Medical Centers - Fort Lauderdale
  • HIV Clinical Research - Fort Lauderdale

Arkansas

  • Health For Life Clinic, PLLC - Little Rock

Colorado

  • Kaiser Permanente - Denver

Connecticut

  • Blick Medical Associates - Norwalk

Trial Details

FieldValue
Enrollment Target 312 participants
Start Date 2008-07
Est. Completion 2011-04
Phase Phase 4

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00724711

The ClinicalTrials.gov registry entry for NCT00724711 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 312 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 239-participant average among 73 other HIV Infection trials with a reported enrollment target (31% higher). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 2 interventions - of which emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the first listed.

NCT00724711 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arkansas.

Frequently Asked Questions

What is clinical trial NCT00724711 about?

NCT00724711 is a clinical study titled "Safety and Efficacy Study of Switching From Epzicom to Truvada". This protocol describes a prospective, randomized, open-label, multicenter study to evaluate the safety and efficacy of switching from fixed dose abacavir (ABC)/lamivudine (3TC) to fixed dose emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in virologically suppressed, human immunodeficiency ...

What is the current status of trial NCT00724711?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 312 participants. The study started on 2008-07. Estimated completion is 2011-04.

What conditions does trial NCT00724711 study?

This clinical trial studies the following conditions: HIV Infection.

What interventions are being tested in trial NCT00724711?

The interventions under investigation include: emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) (DRUG), abacavir (ABC)/lamivudine (3TC) (DRUG).

Who is sponsoring clinical trial NCT00724711?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00724711 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infection

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.